Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melvyn Acosta

Gastroenterology San Juan, PR Medical Doctor

NPI 1811993660 CMS profile 813569

Ave Cesar Gonzalez #576 Adler Center Suite 405, Centro De Gastroenterologia Y Desordenes De Tragad, San Juan, PR 00919

Open in the dashboard

General payments

$58

3 records reported · program years 2021–2025

Research payments

$13,785

Paid to them · 4 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$357,646 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Melvyn Acosta of San Juan, PR is reported in the CMS Open Payments database as having received $58 across 3 general payments and $13,785 in research payments paid to them. Separately, studies naming them as principal investigator received $357,646 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 Research $1,410 2
2023 General $16 1
2023 Research $12,375 2
2022 General $19 1
2021 General $22 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melvyn Acosta
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Melvyn Acosta were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Melvyn Acosta Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $22 $352 $106–$1,054 $132
2022 $19 $448 $129–$1,270 $149
2023 $16 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. E.R. Squibb & Sons, L.L.C. $42 2 payments
  2. Genzyme Corporation $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $58 3 payments
Products named General payments · program years 2021–2025
  1. ZEPOSIA $42 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. AbbVie, Inc. $12,375 2 payments
  2. Eli Lilly and Company $1,410 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

610

Median for Gastroenterology: 569

Drug cost

$22,841

Median for Gastroenterology: $104,976

Branded share of claims

36.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sucralfate Generic 41 $8,227
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 25 $4,188
Suprep Sodium, Potassium,mag Sulfates Brand 30 $3,518
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 115 $2,829
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 13 $962
Famotidine Generic 112 $907
Pantoprazole Sodium Generic 93 $744
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 15 $406
Dicyclomine Hcl Generic 21 $212
Ciprofloxacin Hcl Generic 20 $206

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$12,705

Medicare's payments for the services billed

Medicare patients

57

Average age 73

Services billed

109

29 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 58%
Arthritis 46%
Ischemic heart disease 37%
Cancer 25%
Chronic kidney disease 23%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record